Omnicell, Inc. $OMCL Holdings Raised by AlphaQuest LLC

AlphaQuest LLC lifted its stake in Omnicell, Inc. (NASDAQ:OMCL) by 388.4% in the third quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 24,231 shares of the company’s stock after purchasing an additional 19,270 shares during the quarter. AlphaQuest LLC’s holdings in Omnicell were worth $738,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Raymond James Financial Inc. purchased a new position in shares of Omnicell in the second quarter worth approximately $26,000. First Horizon Corp purchased a new position in Omnicell during the 3rd quarter worth approximately $31,000. Farther Finance Advisors LLC raised its stake in Omnicell by 784.8% during the 3rd quarter. Farther Finance Advisors LLC now owns 1,168 shares of the company’s stock valued at $36,000 after purchasing an additional 1,036 shares during the period. Tower Research Capital LLC TRC lifted its holdings in shares of Omnicell by 385.5% in the second quarter. Tower Research Capital LLC TRC now owns 4,952 shares of the company’s stock valued at $146,000 after purchasing an additional 3,932 shares in the last quarter. Finally, SG Americas Securities LLC lifted its holdings in shares of Omnicell by 6.6% in the third quarter. SG Americas Securities LLC now owns 6,433 shares of the company’s stock valued at $196,000 after purchasing an additional 401 shares in the last quarter. Institutional investors and hedge funds own 97.70% of the company’s stock.

Omnicell Trading Down 5.5%

NASDAQ:OMCL opened at $46.04 on Wednesday. The company has a market capitalization of $2.07 billion, a P/E ratio of 107.07, a P/E/G ratio of 5.19 and a beta of 0.78. The stock’s 50 day moving average price is $45.96 and its 200 day moving average price is $36.84. The company has a debt-to-equity ratio of 0.14, a quick ratio of 1.21 and a current ratio of 1.44. Omnicell, Inc. has a 52 week low of $22.66 and a 52 week high of $55.00.

Analyst Ratings Changes

OMCL has been the topic of a number of research analyst reports. Weiss Ratings reissued a “sell (d+)” rating on shares of Omnicell in a research report on Thursday, January 22nd. Zacks Research cut Omnicell from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, December 9th. Wells Fargo & Company increased their price target on shares of Omnicell from $43.00 to $52.00 and gave the stock an “overweight” rating in a research report on Monday, January 5th. Benchmark boosted their price objective on shares of Omnicell from $50.00 to $60.00 and gave the company a “buy” rating in a research report on Monday. Finally, UBS Group set a $53.00 price objective on shares of Omnicell in a research note on Friday, January 16th. Four investment analysts have rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $50.00.

Insider Activity at Omnicell

In other news, EVP Corey J. Manley sold 6,106 shares of the stock in a transaction on Thursday, January 8th. The shares were sold at an average price of $49.90, for a total transaction of $304,689.40. Following the transaction, the executive vice president owned 91,674 shares in the company, valued at $4,574,532.60. This represents a 6.24% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 2.52% of the stock is currently owned by company insiders.

Omnicell Company Profile

Omnicell, Inc is a healthcare technology company that specializes in medication management solutions for hospitals, clinics and pharmacies. The company’s offerings encompass automated dispensing cabinets, pharmacy automation systems, IV compounding devices, and software platforms designed to optimize medication usage, streamline workflow and improve patient safety. Omnicell’s analytics and inventory management tools provide real-time visibility into medication utilization, helping healthcare providers reduce waste, manage controlled substances and ensure regulatory compliance.

Founded in Mountain View, California in 1992, Omnicell has grown through both internal innovation and strategic acquisitions to broaden its portfolio across the medication management continuum.